FAP-activated anti-tumour compounds

US6613879B1 · kind B1 · utility

Assignees

• BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG · DE
• Boehringer Ingelheim Pharmaceuticals, Inc. · US

Inventors

• Raymond A. Firestone · Ridgefield, US
• Wolfgang J. Rettig · Biberach, DE
• Martin Lenter · Ulm, DE
• Stefan Peters · Biberach an der Riß, DE
• Pilar Garin-Chesa · Biberach, DE
• Juergen Mack · Biberach an der Riß, DE
• Dietmar Leipert · Ingelheim am Rhein, DE
• John Park · Warthausen, DE
• Leila Telan · Wuppertal, DE

Key dates

• Filing date: Apr 21, 2000
• Grant date: Sep 2, 2003
• Expiry date: Apr 21, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.